metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus pembrolizumab plus placebo
	pembrolizumab plus ipilimumab
	KEYNOTE-598, 2020 J Clin Oncol 2021 Jan 29;JCO2003579. NCT03302234	RCT	mNSCLC - L1 - PDL1 positive	pembrolizumab plus ipilimumab	placebo plus pembrolizumab	as first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 with a tumor proportion score (TPS) ≥50% and no EGFR or ALK aberrations	284 / 284	low	inconclusive	inconclusive 8 % increase in deaths (OS) (PE) inconclusive 6 % increase in progression or deaths (PFS) (PE)
versus pemetrexed plus platin
	nivolumab plus ipilimumab
	CheckMate 227 (NI vs C ; PDL1>1%), 2018 Eur J Cancer 2019 Jul;116:137-147. N Engl J Med 2018 May 31;378(22):2093-2104. N Engl J Med 2019 Nov 21;381(21):2020-2031. Oncology (Williston Park) 2020 Jul 15;34(7):254. J Thorac Oncol 2021 Apr;16(4):665-676. J Thorac Oncol. 2021 Oct 11;S1556-0864(21)03207-X NCT02477826	RCT	mNSCLC - L1 - PDL1 positive	nivolumab plus ipilimumab	platinium chemotherapy	patients with histologically confirmed squamous or nonsquamous stage IV or recurrent NSCLC who had received no previous systemic anticancer therapy and PDL1>1%	396 / 397	some concern	conclusif	demonstrated 21 % decrease in deaths (OS) (PE) suggested 18 % decrease in progression or deaths (PFS)
versus Standard of Care (SoC)
	durvalumab plus tremelimumab
	MYSTIC (DT ; PDL1>25%), 2020 JAMA Oncol 2020 May 1;6(5):661-674. NCT02453282	RCT	mNSCLC - L1 - PDL1 positive	durvalumab and tremelimumab	platinum-based doublet chemotherapy	first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%	163 / 162	some concern	inconclusive	inconclusive 15 % decrease in deaths (OS) (PE) inconclusive 5 % increase in progression or deaths (PFS) (PE)